NCT02710734 2024-12-24
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Active not recruiting
Clinical Trials
1 trialsInterventional × Urothelial Carcinoma of the Bladder × Transurethral Resection of Bladder × Clear all